Abstract: Background. Newcastle disease virus (NDV) is a paramyxovirus that is pathogenic in birds but causes only mild flulike symptoms in human beings. NDV(F3aa)-GFP is a genetically modified, fusogenic NDV. We assessed the utility of NDV(F3aa)-GFP in treating head and neck squamous cell carcinoma.
Abstract: Background. Newcastle disease virus (NDV) is a paramyxovirus that is pathogenic in birds but causes only mild flulike symptoms in human beings. NDV(F3aa)-GFP is a genetically modified, fusogenic NDV. We assessed the utility of NDV(F3aa)-GFP in treating head and neck squamous cell carcinoma.
Methods and Results. At a multiplicity of infection (MOI) of 1, NDV(F3aa)-GFP infection of 3 cell lines supported strong GFP expression by 36 hours. Four cell lines were highly sensitivite to viral cytotoxicity, with >75% of cells lysed by day 6 at MOI 0.1, and 2 other cell lines were partially susceptible. Murine SCC25 flank tumors exhibited robust GFP expression after a single intratumoral viral injection and showed near-complete tumor regression over 34 days. There were no adverse effects attributable to therapy.
Conclusions. We demonstrate that a fusogenic NDV exerts potent oncolytic effects against human head and neck cancer and support its continued investigation for clinical application. Approximately 650,000 cases of head and neck cancer are newly diagnosed annually, and this disease is estimated to cause approximately 350,000 deaths yearly worldwide. 1 In the United States, about 36,000 new cases of squamous cell carcinoma involving the oral cavity and pharynx were diagnosed in 2009. 2 Despite progress in advancing surgical techniques and improvement in the delivery of radiotherapy and chemotherapy, the mortality rate of these patients remains significant, particularly for those with advanced malignancies failing conventional therapy.
The development of therapeutic agents with novel mechanisms of activity is needed to improve outcomes for these patients. 3 A variety of viruses have been shown to possess oncolytic, antitumoral activity against cancer, including herpes simplex virus type 1, vaccinia virus, and adenovirus among others. 4 The first report of the utility of Newcastle disease virus (NDV) as a form of treatment for human cancer was published in 1964. 5 Naturally occurring NDV has been shown to be able to lyse human cancer cells directly. 6 NDV has also been used as a form of immunotherapy for neuroblastoma, 7 melanoma, 8, 9 and other malignancies. As a therapeutic agent, NDV possesses several favorable attributes. First, NDV is a paramyxovirus that causes disease in birds, but in human beings only causes mild flulike symptoms. Second, NDV is a single-stranded RNA virus that replicates in the cytoplasm of infected cells without affecting host DNA, reducing the risk of undesired recombination events. Third, genetically modified oncolytic NDV viruses may be engineered, allowing for novel strategies to be incorporated in future vector design to facilitate cancer cell lysis.
A nonpathogenic, chicken vaccine strain of NDV, Hitchner B1 (NDV/B1), was modified by use of an established reverse genetic system to express a modified F protein that contains a multibasic cleavage and activation site; this modified virus was termed NDV(F3aa)-GFP.
10 NDV(F3aa)-GFP is a highly fusogenic virus and is able to form syncytia, which enhanced its oncolytic potential against a murine colon carcinoma cell line. 11 In this study, we evaluated the oncolytic efficacy of NDV(F3aa)-GFP against a panel of human head and neck squamous cell carcinomas in vitro and in a flank tumor model of squamous cell carcinoma in vivo. We found that NDV(F3aa)-GFP possesses potent oncolytic effects in vitro against head and neck cancers. A single intratumoral injection of NDV(F3aa)-GFP into murine flank tumors of SCC25 was able to induce nearly complete tumor regression without any toxicity attributable to viral administration.
MATERIALS AND METHODS
Cell Lines. Six human head and neck squamous cell carcinoma cell lines were studied: MSK 922, MSK QLL1, MDA 1386, MDA 1586, SCC 15, and SCC 25. All cell lines were grown in MEM containing 10% FCS and 1% penicillin and streptomycin. All cells were grown in a humidified incubator at 5% CO 2 and 37 C.
Virus. The NDV mutant viruses with modified F cleavage site (NDV(F3aa)-GFP) were previously described. 10 Briefly, the attenuated NDV of Hitchner B1 strain (NDV-B1) was modified with a reverse-genetics system, and the cleavage site of the F protein was replaced with 3 amino acid changes to create NDV(F3aa)-GFP. To generate NDV(F3aa)-GFP virus expressing green fluorescent protein (GFP), a DNA fragment of GFP flanked by the appropriate NDV-specific RNA transcriptional signals was inserted into the XbaI site created between the P and M genes of pT7NDV/F3aa. Viruses were rescued from cDNA by use of methods described previously and sequenced by reverse transcription-polymerase chain reaction (RT-PCR) for insert fidelity.
10
In Vitro GFP Expression. Cells were plated at 2 Â 10 4 per well in 96-well plates in 100 lL of media per well. After 6 hours of incubation, NDV(F3aa)-GFP in media 50 lL was added to each well at a multiplicity of infection (MOI) of 1. At time points up to 72 hours after infection, cells were examined with an inverted fluorescence microscope (Nikon Eclipse TE300; Nikon, Tokyo, Japan) for GFP expression, and photographs were taken. All samples were analyzed in triplicate.
Cytotoxicity Assays. Each cell line was plated at 2 Â 10 4 cells per well in 12-well plates in media 1 mL. After incubation for 6 hours, NDV(F3aa)-GFP in media 100 lL was added to each well at MOIs of 0.1, 1, and 3. Viral-induced cytotoxicity was measured at daily intervals for 1 week. After the day 3 measurements, additional fresh media 1 mL was added to the remaining wells. Cells were washed with phosphatebuffered saline (PBS) and lysed with Triton X (1.35%; Sigma Chemical Co., St. Louis, MO) to release intracellular lactate dehydrogenase (LDH), which was quantified with a Cytotox 96 kit (Promega, Madison, WI). LDH was detected by the conversion of a tetrazolium salt into a red formazan product that was measured by spectrophotometry (EL321e, Bio-Tek Instruments, Winooski, VT) at 450 nm. Results are expressed as the percentage of surviving cells determined from comparing the LDH of each test sample with untreated samples that were considered 100% viable. The assay was performed on 3 replicate samples for each condition, and mean values and standard errors were plotted. 
RESULTS
In Vitro GFP Expression. NDV(F3aa)-GFP gene expression in 6 SCC cell lines was monitored by GFP expression after infection at MOI 1.0. Very few cells for any cell line expressed visible GFP at 18 hours. MDA 1386, SCC 25, and MDA 1586 supported the greatest GFP expression by 36 hours, followed by MSK 922, and SCC 15. MSK QLL1 showed the lowest levels of GFP expression (Figure 1 ). GFP expression appeared to peak at 36 to 48 hours for MSK 922, SCC 25, and MDA 1586, whereas the peak was later at 72 hours for MDA 1386. All animals were monitored clinically for 34 days. NDV(F3aa)-GFP treated tumors demonstrated nearcomplete tumor volume regression over a 1-month period. By day 34, the mean tumor volume was just 4.7 AE 2.8 mm 3 (standard error, Figures 4 and 5A ). In contrast, all of the control tumors progressively increased in size, and, by day 34, the mean tumor volume of control tumors was 87.7 AE 23.6 mm 3 (p < .001, t test, 2-tailed). There were significant differences between control and NDV(F3aa)-GFP treated tumors at all time points from day 8 and later (p < .01, 2-tailed t test for all comparisons).
Two of the NDV(F3aa)-GFP treated mice were cured by day 22. Mean body weights remained stable for both control and NDV(F3aa)-GFP groups with no significant differences ( Figure 5B ). There was no morbidity and no side effects attributable to NDV(F3aa)-GFP viral therapy during the entire experiment. The experiment was concluded at day 34 because of ulceration of the control tumors.
DISCUSSION
Oncolytic viral therapy is an approach to cancer therapy that harnesses a virus' natural ability to infect, replicate within, and lyse a host cell as part of its natural life cycle. Although a variety of viruses have demonstrated significant oncolytic properties, a major concern when considering their clinical application as a therapeutic agent is their potential for exhibiting harmful, pathogenic behavior. Attenuation strategies have been employed to genetically weaken these viruses and enhance their safety for clinical use. However, the replication-competent abilities of these viruses, and their origins as human pathogens, still remain a concern when designing clinical trials. Newcastle disease virus is a paramyxovirus with pathogenic effects in birds. However, unlike herpes simplex type 1 or adenovirus, NDV does not have significant adverse effects in human beings, with mild flulike symptoms or conjunctivitis as its worst reported symptoms. The relatively innocuous behavior of NDV in human beings makes it attractive as a potential therapeutic biologic agent.
A genetically modified NDV, NDV(F3aa)-GFP, was originally designed with a series of other viral constructs in an attempt to develop a vaccine.
10 NDV(F3aa)-GFP was noted to have a highly fusogenic phenotype, a quality that enables the for-mation of syncytia that may facilitate oncolytic potential.
11 NDV(F3aa)-GFP previously exhibited effective oncolytic ability in a murine model of colon cancer. The purpose of this study was to examine the potential of NDV(F3aa)-GFP to treat a panel of human head and neck squamous cell carcinomas and determine its efficacy in vivo.
Our study demonstrates that NDV(F3aa)-GFP is able to infect and lyse 4 of the 6 squamous cell carcinoma cell lines with high efficiency, with a relatively low MOI of 0.1 resulting in >75% cell lysis by day 6. The remaining 2 cell lines demonstrated partial sensitivity at an MOI of 3, the highest dose tested and could potentially be more susceptible to higher concentrations of NDV(F3aa)-GFP. Interestingly, we did not see a clear correlation between early NDV(F3aa)-GFP gene expression (GFP) and susceptibility to cytotoxicity, suggesting that there are other factors after initial viral infection that may determine a cancer's ultimate response to NDV therapy. A single intratumoral injection of NDV (F3aa)-GFP at a modest dose of 1 Â 10 7 pfu resulted in dramatic tumor regression over a 1-month period, with 2 of 8 animals treated exhibiting complete tumor regression. This in vivo viral dose is similar to the doses that our group has previously used against head and neck cancer flank tumors with genetically modified herpes simplex 12 and vaccinia 13 viruses. Importantly, none of the animals treated with NDV(F3aa)-GFP demonstrated any evidence of viral-induced toxicity, and their body weights remained stable throughout the entire study.
It should be noted that this model (athymic nude mice) does not allow for the induction of a protective/ therapeutic immune response as a result of the infection of the tumor cells. The modulation of the host immune response may significantly increase the efficacy of this approach in humans. Other variants of oncolytic NDV have recently been constructed that incorporate additional therapeutic strategies that may complement direct oncolysis. NDV engineered to express interleukin (IL)-2 enhanced therapeutic potential in a murine model of melanoma.
14 Interestingly, NDV expressing the influenza virus protein NS1, an interferon antagonist, may also enhance therapy against murine melanoma by suppressing host anti-viral immune responses, yet still allowing for the development of an anti-tumoral cytotoxic T lymphocyte response. 15 These recent studies demonstrate that oncolytic NDV may serve as a platform for the design of second-generation vectors to apply additional therapeutic strategies to enhance viral oncolysis.
Conventional treatment for head and neck cancer consists of surgery, radiation therapy, and chemotherapy, applied singularly or in combination, depending on the scenario. Despite refinements in the application of these therapies, the survival rates for patients with head and neck cancers have not significantly improved for decades. Novel therapies with novel mechanisms of activity are necessary to improve stagnant outcomes for these patients, particularly for those with advanced or recurrent head and neck cancer. NDV may represent 1 such novel therapy. NDV is safe in human beings and exhibits natural oncolytic behavior. We demonstrate in this study that a fusogenic variant of a nonpathogenic chicken vaccine strain, NDV(F3aa)-GFP, may infect and induce significant oncolysis against a panel of human head and neck squamous carcinoma cell lines. Importantly, a single intratumoral injection of NDV(F3aa)-GFP led to dramatic tumor regression without any appreciable viral toxicity. These findings support the continued investigation of NDV as a therapeutic agent for head and neck cancer, and merit consideration for application in future clinical trials.
